BioNTech SE (BNTX) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
BNTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BNTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 77.6% | -22.6% | -39.6% |
| 2024 | 80.3% | -47.8% | -24.2% |
| 2023 | 84.3% | 18.1% | 24.4% |
| 2022 | 82.7% | 73.0% | 54.5% |
| 2021 | 84.7% | 80.5% | 54.2% |
Download Data
Export BNTX earnings history in CSV or JSON format
Free sign-in required to download data
BioNTech SE (BNTX) Earnings Overview
As of May 8, 2026, BioNTech SE (BNTX) reported trailing twelve-month net income of -$1.13B, reflecting -62.8% year-over-year growth. The company earned $-4.62 per diluted share over the past four quarters, with a net profit margin of -39.6%.
Looking at the long-term picture, BNTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $10.29B in fiscal 2021.
BioNTech SE is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MRNA (-$3.19B net income, -145.2% margin), PFE ($7.49B net income, 12.4% margin), NVAX (-$88M net income, 39.2% margin), BNTX has outperformed on profitability metrics. Compare BNTX vs MRNA →
BNTX Earnings vs Peers
Earnings metrics vs comparable public companies
BNTX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$1.09B | -64.0% | -$624M | $-4.51 | -39.6% | -22.6% |
| 2024 | -$665M | -171.5% | -$1.31B | $-2.77 | -24.2% | -47.8% |
| 2023 | $930M | -90.1% | $690M | $3.83 | 24.4% | 18.1% |
| 2022 | $9.43B | -8.3% | $12.64B | $37.09 | 54.5% | 73.0% |
| 2021 | $10.29B | +67613.8% | $15.28B | $41.21 | 54.2% | 80.5% |
| 2020 | $15M | +108.5% | -$82M | $0.06 | 3.2% | -17.1% |
| 2019 | -$179M | -273.0% | -$182M | $-0.85 | -164.9% | -167.1% |
| 2018 | -$48M | +43.9% | -$54M | $-0.21 | -37.6% | -42.2% |
| 2017 | -$86M | - | -$61M | $-0.38 | -139.1% | -99.5% |
Full BNTX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BNTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BNTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BNTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBNTX — Frequently Asked Questions
Quick answers to the most common questions about buying BNTX stock.
Is BNTX growing earnings?
BNTX EPS fell to $-4.62, with earnings declining -62.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-1.1B.
What are BNTX's profit margins?
BioNTech SE net margin is -39.6%, with operating margin at -22.6%. Below-average margins reflect competitive or cost pressures.
How consistent are BNTX's earnings?
BNTX earnings data spans 2017-2025. The declining earnings trend is -62.8% YoY. Historical data enables comparison across business cycles.